OxyContin maker, Perdue Pharma, plead guilty to criminal charges for their role in the national opioid crisis. The drug maker is charged with three federal counts and has agreed to pay $8.3 billion dollars as well as shut down its operations. The privately held corporation will forfeit $2 billion of prior profits, pay a civil liability settlement of $2.8 billion and a fine of $3.5 billion. The funds will go towards financing opioid treatment and mitigation programs.
Since Purdue doesn’t have enough liquid assets to cover the cost of the fines, they agreed to dissolve the company as part of the settlement terms. The remaining assets will be redirected to form a “public benefit company” trust fund, which will operate in the interest of victims of the opioid addiction crisis and the American general public.
Tim McDermott, Assistant Administrator for the DEA (Drug Enforcement Administration), said Purdue Pharma deliberately avoided government efforts which “ensure compliance and prevent diversion.” McDermott added “the devastating ripple effect of Purdue’s actions left lives lost and others addicted.”
The new company will still manufacture pain medicines, including OxyContin, which Deputy Attorney General Jeffrey Rosen said has a legitimate role; however, plans also include making opioid rescue kits and overdose medications available to low income communities at deeply discounted prices.
Ann Sullivan is a contributing staff writer covering national and world news topics. She brings dedicated experience having written international and domestic news, blogs, and web content for over 20 years. She’s also a published poet and graphic designer with degrees in Business and Graphic Communications and has been a music distributor, music industry sponsorship sales director and band manager.